Walgreens Boots Alliance: This Dividend Aristocrat Just Proved Retail Isn’t Dead After All - Sure Dividend Sure Dividend

Sure Dividend

High Quality Dividend Stocks, Long-Term Plan
Get Top 10 Stocks in Sure Dividend Newsletter NowGet The 5%+ Yield Sure Retirement Newsletter Now

Walgreens Boots Alliance: This Dividend Aristocrat Just Proved Retail Isn’t Dead After All


Published by Bob Ciura on July 1st, 2017

Walgreens Boots Alliance (WBA) unveiled fiscal third-quarter earnings on June 29th, and the results proved that retail isn’t dead.

Far from it—despite the cascade of bad news that has hit the retail industry over the past year, some retailers are still seeing strong results.

Investors may be convinced that e-commerce retail giant Amazon.com (AMZN) is about to take over the entire industry. But that is far from reality.

Walgreens posted growth in both sales and earnings-per-share, no small feat in this climate.

And, Walgreens has a long track record of rewarding shareholders. It has increased its dividend for 41 years in a row.

It is a Dividend Aristocrat, which is a group of 51 stocks in the S&P 500 Index with 25+ years of consecutive dividend increases.

You can see the entire list of 51 Dividend Aristocrats here.

This article will discuss the key reasons for Walgreens’ continued success, in a very difficult time for the retail industry.

Business Overview

Walgreens Boots Alliance is a global pharmacy giant. It operates all over the world, after the huge merger between Walgreens and Alliance Boots in December 2014.

The combined company is the largest retail pharmacy in the U.S. and Europe.

WBA Overview

Source: Q3 Earnings Presentation, page 16

Walgreens handed in the proverbial “beat-and-raise”. Not only did the company surpass analyst expectations for last quarter’s earnings, but it also raised its forecast for the remainder of the year.

For the quarter, Walgreens had profit of $1.2 billion, on sales of $30.1 billion. Earnings-per-share rose to $1.07, an increase of 5.9% from the same quarter last year.

Adjusted earnings-per-share, which excludes various non-recurring items, were $1.33. This beat analyst expectations, which called for earnings-per-share of $1.30.

Revenue for the quarter also beat analyst forecasts, by approximately $400 million.

In addition, Walgreens raised the low-end of its earnings guidance for the rest of 2017. Full-year earnings-per-share are expected in a range of $4.98-$5.08, up from a prior range of $4.90-$5.08.

Walgreens posted very strong growth rates across the board, particularly after excluding the impact of currency exchange.

WBA Highlights

Source: Q3 Earnings Presentation, page 4

In addition to the quarterly earnings results, the company announced a revised agreement with smaller competitor Rite Aid (RAD), which Walgreens had previously planned to acquire since 2015.

Instead of a full takeover, Walgreens will acquire 2,186 Rite Aid stores, along with associated warehouses and inventory.

The reason for the change is because Walgreens management began to doubt whether an acquisition would receive regulatory approval. The pending deal was subjected to an unusually long review by the Federal Trade Commission, which prompted Walgreens to reconsider.

Despite the failed acquisition attempt, Walgreens still has compelling future growth catalysts.

Growth Prospects

Even though the retail industry is broadly struggling, Walgreens still has growth potential up ahead. The major reason for this is because of Walgreens’ niche.

Pharmaceutical sales are an attractive segment, primarily because of demographics. The U.S. is an aging population, which should result in a sustained increase in demand over the long-term.

This is why Walgreens’ U.S. pharmacy business continues to be the company’s best-performing business. Segment sales increased 10.3% last quarter, thanks to 5.8% growth in comparable-store sales.

WBA Pharmacy USA

Source: Q3 Earnings Presentation, page 7

Prescriptions rose 8.5% for the quarter, the best performance in more than seven years. This performance was due to Medicare Part D growth, as well as volume growth from new pharmacy partnerships.

And, Walgreens’ pharmacy market share increased 110 basis points, to 20.5%. Walgreens commands huge market share in a growing business, which is a great sign for the future.

Another growth catalyst is Walgreens’ pharmaceutical wholesale business, operating under the Alliance Healthcare brand.

Constant-currency comparable sales increased 3.7% last quarter, and adjusted operating profit soared 53% year over year in the pharmaceutical wholesale segment.

Competitive Advantages & Recession Performance

Walgreens Boots Alliance’s biggest competitive advantage is scale. It has a presence in more than 25 countries around the world.

It currently operates over 13,000 stores, along with over 390 distribution centers. This provides the company with economies of scale, which allows the company to pressure suppliers for low prices.

Companies like Wal-Mart (WMT) or Costco (COST) pass these savings onto consumers.  Walgreens sells its goods for higher prices than traditional discount retailers.  The company’s convenient corner store locations, smaller store sizes, and pharmacy entice consumers to buy goods at slightly higher prices.  The effect can be seen in Walgreens’ operating margin in its retail business:

Separately, Walgreens benefits from a strong brand. Its long operating history and huge number of stores make Walgreens a popular destination for customers who need prescriptions filled or health care products.

These competitive advantages help provide Walgreens with a recession-resistant business.

Consumers cannot go without prescriptions and health care products, which help Walgreens generate steady profits each year, even when the economy goes into recession.

Walgreens suffered only a slight decline in earnings-per-share during the Great Recession, followed by a quick recovery:

Walgreens’ consistent profitability provides a solid floor underneath the stock valuation.

Valuation & Expected Total Returns

In the trailing four fiscal quarters, Walgreens generated adjusted earnings-per-share of $4.86. On this basis, the stock trades for a trailing price-to-earnings ratio of 16.

This is significantly below the valuation of the S&P 500 Index, which trades for an average price-to-earnings ratio of 26.

Based on Walgreens’ high-quality business model, growth potential, and low valuation, the stock appears to be undervalued.

An expanding valuation multiple could generate significant returns, as will Walgreens’ earnings growth and dividends.

A reasonable breakdown of potential returns is as follows:

As a result, the stock could generate 9%-11% annualized returns moving forward, with the added potential of an expanding price-to-earnings multiple.

Cash returns will make up a significant portion of shareholder returns going forward.

For example, along with its quarterly earnings results, the company announced a new $5 billion share repurchase authorization.

The buybacks will be conducted over the next year, and represent approximately 6% of the company’s market cap.

If the company utilizes the entire $5 billion, total shareholder returns could be even greater.

Final Thoughts

This is a very challenging time for retail, but not all retailers are struggling.

Walgreens remains very healthy. Its sales and earnings are growing, which allows the company to pursue new strategic growth initiatives, buy back stock, and raise its dividend.

Walgreens has raised its dividend each year for more than four decades, which speaks to the strength of its business model.

As a result, Walgreens is an attractive stock for dividend growth investors.


See Our Best ideas
Get Top 10 Stocks in Sure Dividend Newsletter NowGet The 5%+ Yield Sure Retirement Newsletter Now